预约演示

更新于：2025-12-04

Albumin-Bound Paclitaxel

白蛋白结合型紫杉醇

更新于：2025-12-04

概要

基本信息

药物类型

小分子化药

别名

Nab-Paclitaxel、Nab-PTX、paclitaxel protein-bound

+ [16]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [5]

在研适应症

转移性胰腺癌胰腺癌转移性胰腺腺癌+ [29]

非在研适应症

大肠腺癌小肠腺癌腺鳞癌+ [117]

原研机构

Abraxis BioScience, Inc.

在研机构

Hoffmann-La Roche, Inc.WhiteOak Pharmaceutical BV

Bristol Myers Squibb Co.

+ [10]

非在研机构

Genentech, Inc.

GSK Plc

Amgen, Inc.

+ [12]

权益机构

浙江海昶生物医药股份有限公司

BeOne Medicines Ltd.

科兴生物制药股份有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2005-01-07),

转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,195

项与白蛋白结合型紫杉醇相关的临床试验

NCT06592664

/ Withdrawn临床1/2期

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2030-01-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT07253662

/ Not yet recruiting临床1期IIT

Phase I Trial of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Palliative systemic therapy is the standard treatment option for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal metastasis (PM), who have a median overall survival of only 6-11 months and a serious adverse event (SAE) rate of >5%. Patients with peritoneal-only metastasis may demonstrate unique tumor biology with less potential for hematogenous and lymphatic spread, making them potential candidates for a regional approach directed at the peritoneum. PIPAC is a drug- delivery system that combines the pharmacokinetic advantages of low- dose intraperitoneal chemotherapy (high tumor tissue penetration with low systemic absorption/toxicity) with the principles of aerosolization (homogenous intraperitoneal distribution and deeper tissue penetration). PIPAC may offer a complimentary approach to maximize drug delivery to tumor implants, potentially improving quality of life and survival without significant additional morbidity. Several non-randomized studies have evaluated safety, feasibility, and efficacy of PIPAC with various intraperitoneal agents in a variety of tumor types. Very few patients with pancreatic cancer PM have been included in these studies and most have been treated with either PIPAC-oxaliplatin or doxorubicin/cisplatin. A recent phase 1 dose-escalation study included patients with ovarian, gastric, breast, and hepatopancreatobiliary malignancies. One patient with
pancreatic cancer was included in this study. The recommended phase 2 dose was 140 mg/m2, with guidance to decrease the dose to 112.5 mg/m2 in patients with hepatic impairment. Therefore, the dose utilized in this study is 112.5 mg/m2. This recommendation was based on concern for nab-paclitaxel hepatotoxicity, but there was no data presented to support this expert recommendation.
This study sets out to explore the role of PIPAC with nab-paclitaxel in combination with medical oncology choice standard of care therapy in this patient population.

开始日期2026-12-30

申办/合作机构

Northwell Health, Inc.

NCT06998940

/ Not yet recruiting临床3期IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

32,073

项与白蛋白结合型紫杉醇相关的文献（医药）

2026-02-01·BIOMATERIALS

Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma

Article

作者: Song, Haolin ; Sun, Tao ; Jiang, Chen ; Fan, Hongrui ; Cheng, Leilei ; Chen, Qinjun ; Su, Boyu ; Wang, Yu ; Li, Xuwen

Metabolic reprogramming in pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge to the efficacy of gemcitabine-based chemotherapy. Aberrant activation of intracellular pyrimidine metabolism is a key factor contributing to the reduced effectiveness of gemcitabine. Combining gemcitabine with metabolic regulators targeting critical pathways may alleviate gemcitabine resistance. In this study, we focus on the abnormal activation of dihydroorotate dehydrogenase (DHODH) in PDAC cells, a pivotal enzyme in the de novo pyrimidine synthesis pathway that diminishes cellular sensitivity to gemcitabine and catalyzes the reduction of ubiquinone to ubiquinol, playing an essential role in maintaining cellular redox homeostasis. To address these challenges, we developed GE11 peptide-modified polyphenol-iron chelate nanoparticles for co-delivery the long carbon chain-modified gemcitabine and the DHODH inhibitor leflunomide, with peptide modification enabling nanoparticles to target PDAC cells with high expression of epidermal growth factor receptor. The nanoparticles demonstrated the ability to induce mitocytosis and achieve deep tumor penetration in PDAC tissues. Upon drug release at the core lesion, the three components, modified gemcitabine, leflunomide and iron ions synergistically enhanced tumor cell killing by alleviating gemcitabine resistance and disrupting cellular redox homeostasis to induce multimodal cell death. In an in situ pancreatic cancer mouse model, this strategy exhibited superior anti-tumor efficacy compared to the standard AG chemotherapy regimen (nab-paclitaxel and gemcitabine), even at a 6.3-fold lower gemcitabine concentration. These findings underscore the potential of this approach as a highly effective therapeutic strategy for PDAC treatment.

2026-02-01·SURGICAL ONCOLOGY-OXFORD

Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy

Article

作者: Kimura, Yuta ; Ioka, Tatsuya ; Takahashi, Hidenori ; Nakagami, Yuki ; Tokumitsu, Yukio ; Nakajima, Masao ; Matsui, Hiroto ; Watanabe, Yusaku ; Nishiyama, Mitsuo ; Tomochika, Shinobu ; Tsunedomi, Ryouichi ; Iida, Michihisa ; Nagano, Hiroaki ; Shindo, Yoshitaro

BACKGROUND:

The optimal treatment strategy for resectable pancreatic ductal adenocarcinoma (R-PDAC) remains controversial. In this study, we aimed to evaluate the impact of neoadjuvant chemotherapy (NAC) using gemcitabine plus nab-paclitaxel (GnP) or modified FOLFIRINOX (mFFX) compared with upfront surgery (UFS) in patients with R-PDAC.

METHODS:

This retrospective cohort study included 125 patients diagnosed with R-PDAC at a single institution between 2010 and 2022. The patients were divided into UFS (n = 57) and NAC (n = 68) groups. Survival outcomes, perioperative factors, and prognostic variables were analyzed. Subgroup analysis was performed based on high-risk features, defined as elevated carcinoembryonic antigen (CEA) levels >6 ng/mL and tumor size ≥25 mm.

RESULTS:

No significant differences were observed in overall survival (OS) and progression-free survival (PFS) between the entire UFS and NAC groups. However, in patients with high-risk features, NAC significantly improved OS compared with UFS (median survival 29.0 months vs. 10.6 months, respectively; P < 0.0001). NAC was associated with reduced intraoperative blood loss and a lower lymph node positivity rate without increasing postoperative morbidity or mortality.

CONCLUSIONS:

While NAC did not universally improve survival outcomes in R-PDAC, it significantly benefitted patients with poor prognostic indicators. These findings support a selective approach to NAC based on biological risk stratification rather than anatomical criteria alone. Future prospective studies are warranted to validate these observations and optimize individualized treatment strategies.

2026-01-01·Journal of Geriatric Oncology

Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma

Article

作者: Iacomini, Chiara ; Di Giorgi, Nicoletta ; Tortora, Giampaolo ; Trovato, Giovanni ; Cosmai, Antonia ; Bensi, Maria ; Salvatore, Lisa ; Lenkowicz, Jacopo ; Di Francesco, Linda ; Chiofalo, Laura ; Bagalà, Cinzia ; Spring, Alexia

INTRODUCTION:

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis, particularly in older patients (≥70 years), who represent an increasing proportion of cases. However, this population is underrepresented in clinical trials. This study aimed to evaluate the prognostic impact of the Geriatric 8 (G8) screening tool and the comprehensive geriatric assessment (CGA) in older patients with advanced PDAC.

MATERIALS AND METHODS:

We conducted a retrospective observational study of patients aged ≥70 years with locally advanced or metastatic PDAC treated at Fondazione Policlinico Gemelli IRCCS between January 2018 and August 2023. Clinical, demographic, and treatment data were extracted through structured and unstructured data mining. All patients underwent G8 screening at the start of first-line therapy; if G8 was ≤14, patients could have received CGA. Primary endpoints were progression-free survival (PFS) and overall survival (OS), analyzed through Kaplan-Meier estimates and Cox regression models.

RESULTS:

Of 268 eligible older patients, 210 (78.4 %) received first-line chemotherapy. Most received gemcitabine plus nab-paclitaxel (58.1 %). Median PFS and OS were 6.5 (95 % CI: 5.7-7.3) and 9.9 months (95 % CI: 9.1-11.7), respectively. Baseline Geriatric 8 score was ≤14 in 149 out of 210 (70.9 %) patients and ≥ 15 in 61 out of 210 (29.1 %). A baseline G8 score ≥ 15 was significantly associated with higher PFS (7.9 vs. 5.3 months, HR 0.57, p = 0.001) and OS (16.6 vs. 7.8 months, HR 0.39, p < 0.001), both at univariate and multivariate analyses. Among the 149 patients with a baseline G8 ≤ 14, 97 (65.1 %) were referred for CGA, and 60 (40.3 % of the overall G8 ≤ 14 population) completed the assessment. No difference in mPFS (p = 0.28) nor in mOS (p = 0.25) emerged according to CGA assessment. However, the 12-month survival rate was higher in patients who underwent CGA (31.8 %) compared with those who did not (14.2 %).

DISCUSSION:

First-line chemotherapy provides particular clinical benefit to older adults with PDAC with higher G8 scores, though benefit was observed across the broader cohort. The G8 score was a strong independent prognostic tool for treatment response and survival.

1,898

项与白蛋白结合型紫杉醇相关的新闻（医药）

2025-12-04

·ioncology

瞭望前瞻丨SABCS 2025盛幕将启，中国之声亮相世界舞台（Poster Session 1精选）

编者按：第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B. Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特别对Rapid Fire、Poster Spotlight、Poster Session等环节中国专家的报告内容进行汇总，以便读者快速了解会议动态。本文将介绍Poster Session 1环节入选中国研究，敬请关注后续详细报道！（注：如有遗漏或错误，欢迎留言指正。） Poster Session 1 时间：12月10日12:30 PM–2:00 PM CST 地点：Exhibit Hall 摘要号：PS1-03-01 Secondary prevention of cancer therapy-induced thrombocytopenia with hetrombopag in breast cancer: a prospective,multi-center,self-controlled exploratory trial 乳腺癌治疗相关性血小板减少症的二级预防：一项海曲泊帕前瞻性、多中心、自身对照探索性试验讲者：闫敏（河南省肿瘤医院）摘要号：PS1-03-04 Predictive Factors of Thyroid Adverse Events in Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer 三阴性乳腺癌新辅助免疫治疗中甲状腺不良事件的预测因素讲者：Yumeng Li（中国医科大学附属第一医院）摘要号：PS1-03-15 A Randomized Double-Blind Controlled Study on La Roche-Posay New B5 Multi-Effect Soothing and Repairing Cream in the Treatment of Skin Adverse Reactions Related to EGFR Inhibitors and Capecitabine 理肤泉新B5多效舒缓修复霜治疗EGFR抑制剂和卡培他滨相关皮肤不良反应的随机双盲对照研究讲者：Xueqi Yan（江苏省人民医院）摘要号：PS1-03-26 Changing patterns of attention network in Breast Cancer Survivors 乳腺癌幸存者注意网络模式的变化讲者：Jingjing Li（安徽医科大学第二附属医院）摘要号：PS1-03-27 Impact of Trastuzumab Emtansine with DoseEscalation on Thrombocytopenia inChinesePatientswithHER2-Positive Breast Cancer: A Multicenter Retrospective Study T-DM1剂量递增对中国HER2阳性乳腺癌患者血小板减少的影响：一项多中心回顾性研究讲者：Meng Wang（四川省肿瘤医院）摘要号：PS1-02-09 Association between financial toxicity and mental health among metastatic breast cancer survivors 转移性乳腺癌幸存者的经济困境与心理健康之间的关联讲者：Haoting Shi（Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China）摘要号：PS1-06-01 Predictive Value of Breast-Specific Gamma Imaging for Pathologic Response and Prognosis in Early Breast Cancer After Neoadjuvant Therapy: A Prospective Trial 乳腺特异性伽马显像对新辅助治疗后早期乳腺癌病理反应和预后的预测价值：一项前瞻性试验讲者：Tianyi Qian（浙江大学医学院附属第二医院）摘要号：PS1-06-05 The Early and Late Predictive Value of 18F-FAPI-42 PET/MRI for Neoadjuvant Therapy Response in Breast Cancer: A Prospective Study 18F-FAPI-42 PET/MRI对乳腺癌新辅助治疗反应的早期和晚期预测价值：一项前瞻性研究讲者：Sihua Liu（中山大学附属第一医院）摘要号：PS1-07-25 The Impact of Post Mastectomy Radiotherapy(PMRT) on T1-2N0-1 Male Breast Cancer(MBC) and establishment of an artificial neural network(ANN) predicting model: Population-Based Study 乳房切除术后放疗（PMRT）对T1-2N0-1男性乳腺癌（MBC）的影响及人工神经网络（ANN）预测模型的建立：基于人群的研究讲者：Kaiyan Huang（福建医科大学附属第二医院）摘要号：PS1-10-10 Chidamide combined with fulvestrant in the treatment of HR-positive,HER2-negative advanced breast cancer after failure of previous endocrine therapy: A single-arm, single-center, phase 2 study 西达本胺联合氟维司群治疗既往内分泌治疗失败的HR+/HER2-晚期乳腺癌：一项单臂、单中心、2期研究讲者：La Zou（重庆大学附属肿瘤医院）摘要号：PS1-12-03 Aberrant exon skipping of ALDOA confers tamoxifen resistance in breast cancer ALDOA异常外显子跳跃导致乳腺癌对他莫昔芬耐药讲者：Ying Duan（扬州大学）摘要号：PS1-09-09 Prognostic significance of chemotherapy-related amenorrhea in premenopausal women with de novo metastatic breast cancer 化疗相关的闭经对绝经前新发转移性乳腺癌患者的预后意义讲者：Chongxi Ren（沧州中西医结合医院）摘要号：PS1-09-22 Single-cell RNA Sequencing Reveals Intrathecal Treatment Sensitivity and Regulatory Mechanisms in Breast Cancer Leptomeningeal Metastasis 单细胞RNA测序揭示了乳腺癌软脑膜转移的鞘内治疗敏感性和调节机制讲者：Jizhuo Gao（大连医科大学附属第二医院）摘要号：PS1-09-24 Efficacy and safety of Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-blind Phase III study 白蛋白结合型紫杉醇（SYHX2011）治疗晚期乳腺癌患者的疗效和安全性：一项多中心、随机、双盲III期研究讲者：耿翠芝（河北医科大学第四医院）摘要号：PS1-09-26 Phase II Trial of Anlotinib-Chemotherapy Combination in HER2-Negative Metastatic Breast Cancer: Therapeutic Efficacy and Proteomic Biomarker Profiling 安罗替尼联合化疗治疗HER2阴性转移性乳腺癌的II期试验：疗效和蛋白质组学生物标志物谱讲者：Ting Xu（江苏省肿瘤医院）摘要号：PS1-05-13 Cryotherapy combined with compression gloves and socks therapy reduce nab-paclitaxel-induced peripheral neuropathy in breast cancer patients undergoing neoadjuvant chemotherapy: a multicenter randomized controlled trial 冷冻联合加压手套和袜子疗法减少接受新辅助化疗的乳腺癌患者白蛋白结合型紫杉醇引起的周围神经病变：一项多中心随机对照试验讲者：Lize Wang（北京大学肿瘤医院）摘要号：PS1-08-05 First disclosure of efficacy and safety data for YL202/BNT326 (HER3 antibody-drug conjugate [ADC]) in advanced or metastatic HR+/HER2 null and HER2-low breast cancer: Phase 2 trial results 首次披露YL202/BNT326（HER3抗体-药物偶联物[ADC]）治疗晚期或转移性HR+/HER2零表达和HER2低表达乳腺癌的疗效和安全性数据：2期试验结果讲者：张剑（复旦大学附属肿瘤医院）摘要号：PS1-06-30 Predicting pathological response to neoadjuvant therapy in HER2-positive breast cancer by using 68Ga-HER2 PET/CT: a prospective study 68Ga-HER2 PET/CT预测HER2阳性乳腺癌新辅助治疗病理反应的前瞻性研究讲者：刘运江（河北医科大学第四医院）摘要号：PS1-08-26 A phase 1/2, multi-part, open-label study of FWD1802, a novel oral selective estrogen receptor degrader (SERD), in patients with ER+/ HER2- locally advanced or metastatic breast cancer (BC) FWD1802是一种新型口服选择性雌激素受体降解剂（SERD），用于ER+/ HER2-局部晚期或转移性乳腺癌（BC）患者的1/2期、多部分、开放标签研究讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：PS1-13-28 Integration of NIR-II Imaging and Molecular Profiling Identifies Subtypes of Metastatic Sentinel Lymph Nodes in Breast Cancer NIR-II成像和分子谱分析的整合确定乳腺癌转移性前哨淋巴结的亚型讲者：张国君（云南省肿瘤医院）摘要号：PS1-11-24 Effectiveness of Initial Denosumab Versus Sequential Bisphosphonate-to-Denosumab Therapy in Preventing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases: A Retrospective Single-Center Study 在乳腺癌骨转移患者中，初始地诺单抗与序贯双膦酸盐-地诺单抗治疗在预防骨相关事件方面的效果比较：一项回顾性单中心研究讲者：曹君（复旦大学附属肿瘤医院）（来源：《肿瘤瞭望-乳腺时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2025-12-04

·医药观澜

2025年分子胶新药研发迎新进展，针对癌症等多个疾病领域丨同行致远

编者按：分子胶作为一种新兴的药物治疗模式，通过促使两种蛋白特异性结合而发挥作用，为攻克众多传统手段难以触及的致病蛋白提供了新的策略。尽管前景广阔，分子胶的发现仍是一项极具挑战性的科研任务。药明康德依托其一体化药物发现平台，融合了DNA编码化合物库（DEL）、亲和筛选质谱（ASMS）以及高通量筛选（HTS）等多项前沿技术，为全球合作伙伴提供高效、系统的解决方案，携手加速将分子胶从科研构想到临床现实的转化进程。本文将盘点2025年以来全球范围内分子胶研发管线迎来的新进展，这些进展涉及癌症、炎症性疾病等多个疾病领域。 “分子胶”，顾名思义，它就像一种粘合剂，通过特异性指引两种或多种大分子结合在一起，进而产生特定的生物学效应。作为作为蛋白降解剂（TPD）的重要类型之一，分子胶降解剂可诱导E3泛素连接酶底物受体与靶蛋白之间新型相互作用，从而导致靶蛋白降解。由于减轻了对靶蛋白上的活性相关口袋的需求，这类药物有潜力实现对传统“不可成药”靶点的降解，亦或是信号通路的抑制和激活，从而在诸多疾病领域打开治疗新局面。 2025年分子胶在研管线研究进展盘点 2025年以来，分子胶研发管线取得一系列新进展，适应症涉及非小细胞肺癌、前列腺癌、多发性骨髓瘤等癌症，以及炎症和代谢等疾病等。 12月，Pin Therapeutics公司基于其创新“p53合成激活”机制开发的口服CK1α选择性降解剂PIN-5018已在1期临床试验中完成首例患者给药。该患者罹患腺样囊性癌（ACC）——一种罕见且治疗选择有限的恶性肿瘤。在两个患者来源异种移植ACC模型中，PIN-5018展现出抗肿瘤活性：其中一模型实现完全缓解（CR），另一模型出现明显肿瘤缩小，为推进临床研究提供了有力支持。CK1α是一种由CSNK1A1基因编码的丝氨酸/苏氨酸蛋白激酶，已被证实对许多不同类型的恶性血液肿瘤和实体瘤的生长和存活至关重要。 12月，达歌生物宣布其针对靶点HuR（Human antigen R）的分子胶降解剂DEG6498，已在中国完成首位临床试验受试者给药，由此正式启动首次人体1期研究。HuR是一种RNA结合蛋白，它在癌症、炎症和代谢等疾病的进程中发挥着关键性的作用，此前被业界认为是无法成药的靶点。DEG6498能诱导E3泛素化连接酶Cereblon（CRBN）与RNA结合蛋白HuR的相互作用，从而促进HuR蛋白的靶向降解。 11月，康朴生物公布分子胶降解剂epaldeudomide (KPG-818) 用于治疗血液肿瘤的1期临床试验结果。在既往接受过两个度胺类药物、至少一种蛋白酶抑制剂及一种抗CD38单抗的难治或复发多发性骨髓瘤患者（RRMM）中，KPG-818与地塞米松联用疗效显著，客观缓解率（ORR）为50%，疾病控制率（DCR）为94%。KPG-818归属E3泛素连接酶复合物CRL4-CRBN调节剂，对靶点CRBN具有高亲和力，可以高效降解锌指转录因子Aiolos（IKZF3）和Ikaros（IKZF1），具有广谱免疫调节、抗血管生成和抗肿瘤作用。 10月，Revolution Medicines宣布，其在研RAS（ON）G12C选择性抑制剂elironrasib（RMC-6291）在既往接受过KRAS（OFF）G12C抑制剂治疗的KRAS G12C突变型非小细胞肺癌（NSCLC）患者中，获得了积极临床数据。Elironrasib是一款非降解型分子胶，通过将KRAS G12C和cyclophilin A粘合在一起，形成的三元复合体阻断处于激活状态（ON）的KRAS G12C与RAS效应蛋白结合，从而抑制下游信号传导。分析显示，elironrasib展现出显著的抗肿瘤活性，确认的ORR为42%，DCR为79%。中位缓解持续时间为11.2个月，中位无进展生存期（mPFS）为6.2个月，中位总生存期（OS）尚未达到，12个月总生存率为62%。Elironrasib还于今年7月获美国FDA授予突破性疗法认定，用于治疗局部晚期或转移性KRAS G12C突变型NSCLC成人患者。 9月，Revolution Medicines公司宣布了daraxonrasib（RMC-6236）的1期临床试验最新进展。Daraxonrasib是一款泛KRAS分子胶抑制剂，借助天然产物中的关键结构单元，成功招募了cyclophilin这一呈递蛋白，实现了对激活态RAS蛋白的特异性靶向与有效抑制。在二线及以上转移性胰腺导管腺癌（PDAC）患者中，携带RAS G12X突变或携带任何RAS突变患者，其确认ORR分别为35%与29%，DCR分别为92%与95%。在一线转移性PDAC患者中，daraxonrasib 300mg QD单药治疗同样取得了积极结果，在具足够随访时长的38例患者中，ORR达47%，DCR达89%，中位随访时间为9.3个月；联合吉西他滨和白蛋白紫杉醇（GnP）的组合方案在一线转移性PDAC中展现出更高的缓解率，在具有足够随访时长的31例患者中，ORR达到55%，DCR为90%。该疗法曾在今年6月获FDA授予突破性疗法认定，用于治疗既往接受治疗、携带KRAS G12突变的转移性PDAC患者。 9月，C4 Therapeutics公司公布了靶向IKZF1/3的在研分子胶cemsidomide治疗MM患者的1期临床试验结果。在接受过多线治疗的RRMM患者中，cemsidomide联合地塞米松展现出强劲且持久的抗肿瘤活性。最高剂量组（100 µg）患者的ORR达50%；75 µg剂量组的ORR为40%。所有剂量组的中位缓解持续时间（DOR）为9.3个月。该公司计划在2026年初启动注册性临床试验。药效学结果显示，该产品与地塞米松联用可高效降解靶蛋白并激活T细胞，在人外周血单核细胞中，IKZF1的降解率＞50%、IKZF3降解率＞80%，且在所有剂量下均显著增强T细胞活化和IL-2等细胞因子的产生。 8月，Monte Rosa Therapeutics公司开发的靶向NEK7的分子胶蛋白降解剂MRT-8102，在1期临床试验中已完成首例患者给药。这款口服选择性分子胶降解剂有望用于治疗与NLRP3、IL-1β和IL-6失调相关的炎症性疾病。此外今年3月，Monte Rosa Therapeutics公司还在第四季度季报中公布了多款在研分子胶降解剂的最新临床试验结果。其中，靶向降解GSPT1的分子胶降解剂MRT-2359，在治疗对雄激素受体靶向疗法耐药的去势抵抗性前列腺癌患者时表现出抗癌活性，这些患者的肿瘤广泛表达c-MYC。靶向VAV1的分子胶降解剂MRT-6160，在健康志愿者中进行的1期临床试验中表现出良好的安全性和耐受性，并且可将外周血T细胞中的VAV1水平降低超过90%。 6月，百时美施贵宝在欧洲血液学协会（EHA）年会上展示了其蛋白降解剂研发进展。其中，靶向Ikaros/Aiolos的新型E3泛素连接酶Cereblon（CELMoD）分子胶药物golcadomide联合利妥昔单抗治疗复发/难治性滤泡性淋巴瘤疗效显著，ORR达94%，CR率为63%。该产品针对弥漫性大B细胞淋巴瘤,滤泡性淋巴瘤已经进入3期临床研究阶段。另外两款CELMoD分子胶药物mezigdomide和iberdomide也披露了在多发性骨髓瘤患者中的更新临床研究结果，这两款产品均已经进入3期临床研究阶段，针对适应症为多发性骨髓瘤。 5月，百时美施贵宝于美国癌症研究协会（AACR）年会公布了在研的BMS-986449的其化学结构。这是一款Cereblon E3连接酶调节药物（CELMoD）类分子胶降解剂，能够选择性降解调节性T细胞（Tregs）中的关键转录因子Helios（IKZF2）和Eos（IKZF4）。该分子通过重塑Tregs为效应型细胞，增强机体的抗肿瘤免疫应答。在同源性肿瘤模型中，BMS-986449展现出良好的抗肿瘤活性，并在食蟹猴中实现超过80%的Helios降解率。除了上述产品，还有多款新药获批临床，进入新药研发的新阶段，包括： 11月，万春宏基医药、人福利康药业共同申报的1类新药ST-01156胶囊在中国获批临床，拟开发治疗晚期或转移性恶性实体瘤。这是一种口服、可经血脑屏障的RBM39靶向分子胶降解剂。RBM39是一种重要的RNA剪接和转录调控因子，它在多种癌症中过表达。 9月，劲方医药1类新药GFH276片在中国获批临床，拟开发治疗RAS突变阳性或KRAS扩增的晚期实体瘤患者。这是一款口服Pan RAS（ON）抑制剂分子胶新药，可抑制多数野生/突变型RAS蛋白，在多种携带RAS突变或RTK改变的细胞及肿瘤模型中显示抑瘤活性。 2月，嘉越医药1类新药JYP0015片在中国获批临床，拟开发治疗RAS突变的血液瘤和实体瘤。这是一款泛RAS抑制剂分子胶产品，它可以通过形成RAS-亲环蛋白A蛋白复合物来阻止RAS介导的信号传导。除了上述进展，2025年分子胶新药研发领域还迎来多项其他进展，此处不再一一列举。一体化CRDMO平台助力分子胶新药研发通过公开渠道梳理，目前全球范围内有数十款在研分子胶新药正处于积极的临床研究阶段。这些新药的靶点包括CK1α、HuR、RAS、IKZF1/3、PRMT5、NEK7、GSPT1、VAV1、RBM39等等，适应症涉及癌症、自身免疫性疾病、神经系统疾病等领域。尽管前景广阔，分子胶的发现仍是一项极具挑战性的科研任务。其功能依赖于在复杂的细胞环境中诱导蛋白间精准的相互作用，而这一过程通常难以预测。即便是轻微的化学修饰，也可能显著改变其活性。因此，若要充分释放分子胶的治疗潜力，必须依赖大规模、系统化的筛选方法与前沿研究策略。药明康德依托其一体化药物发现平台，融合了DNA编码化合物库（DEL）、亲和筛选质谱（ASMS）以及高通量筛选（HTS）等多项前沿技术，为全球合作伙伴提供高效、系统的解决方案，携手加速将分子胶从科研构想到临床现实的转化进程。在分子胶药物研发的早期阶段，在无偏倚药物筛选时的低命中率始终是一项亟待突破的挑战。为助力合作伙伴有效应对这一难题，药明康德采取了“双轨并进”的策略，构建起一套兼顾广度与深度的化合物库体系：一方面，通过多样化的DNA编码化合物库（DEL）大范围探索新靶点；另一方面，借助聚焦化合物库精细化研究已知蛋白体系，提升发现效率。在广度探索方面，药明康德构建的多样化DEL库现已汇集超过500亿种结构各异的小分子，每一个化合物都带有独特的DNA条形码，便于快速识别。这些分子骨架多基于已上市药物或临床候选分子，涵盖数千种具有潜在活性的结构母体，构成了一个化学多样性极高、设计精良的化学空间，尤其适用于靶点尚未明确、或缺乏先例的分子胶研究。在对已知分子胶系统的深入探索中，聚焦化合物库则充分利用现有分子胶结构知识进行靶向设计。例如，针对E3连接酶cereblon（CRBN）的免疫调节药物（IMiDs）化合物库便是典型案例。通过对该蛋白互作区域进行系统性化学修饰，药明康德构建了约600万个精炼化合物，专注于基于CRBN的分子胶发现，有效提升了命中高亲和力、高特异性分子胶的概率，显著增强了对已有构效信息靶点的筛选效率。通过这套双重策略，药明康德不仅拓宽了分子胶药物的发现空间，也为合作伙伴在“未知”与“已知”之间搭建起一座通往临床应用的高效桥梁。在协助客户推进分子胶药物筛选方面，药明康德针对不同形式的DEL库建立了两套成熟的筛选流程。针对液相DEL，采用下拉实验（pull-down assay），对比单蛋白与双蛋白条件下的化合物富集的差异，以筛选出能促使两种蛋白结合的潜在分子胶；而针对固相载体DEL，则结合荧光标记与细胞分选技术，通过可视化筛选找出可同时结合两种蛋白的微珠，随后进行DNA标签测序，明确化合物结构。这两种筛选路径相辅相成、各展所长，一方面拓宽了筛选维度，另一方面也显著提高了高亲和力配体的命中率，加快了分子胶早期研发节奏。在分子胶药物的早期发现过程中，药明康德不仅依赖DNA编码化合物库进行筛选，还不断引入并整合多种先进技术，以助力合作伙伴拓展分子胶药物的发现能力。其中，亲和筛选质谱（ASMS）提供无标记筛选手段。药明康德构建了一个涵盖超过37万个小分子的广谱化合物库，通过比较这些分子在单蛋白与双蛋白条件下的质谱信号差异，精准识别出能够促进蛋白–蛋白相互作用的潜在分子胶候选物，从而识别出潜在促互作的小分子。与此同时，药明康德还部署高通量筛选（HTS）技术。在“一孔一化合物”的自动化运行模式下，结合蛋白结合能力或降解能力等功能性实验，HTS能迅速锁定具备生物活性的候选分子，大幅提升筛选效率与准确性。通过将ASMS与HTS等多维筛选工具与DEL平台深度融合，药明康德打破了单一筛选方式的限制，让更多不同类型的靶点进入分子胶研究视野，进一步拓宽了分子胶在多类靶点上的研发空间。依托一体化平台与多维筛选技术，药明康德已构建起覆盖分子胶药物发现全周期的综合解决方案，助力合作伙伴加速从科学突破迈向临床转化。分子胶作为蛋白降解疗法的关键方向，已在多个疾病治疗领域展现出广阔前景。在科学创新持续造福患者的进程中，药明康德将继续依托一体化、端到端的CRDMO赋能平台，携手全球合作伙伴加速创新药物的研发与生产，助力科学突破早日惠及患者。参考资料： [1] Molecular Glues Discovery: Challenges and Opportunities. Retrieved July 4, 2025 from https://wuxibiology.com/resource/discovery-of-molecular-glues-challenges-and-opportunities/ [2]同行致远 | 破解“不可成药”：一体化平台赋能创新分子胶药物发现 | Bilingual.From https://mp.weixin.qq.com/s?__biz=MzAwMDA5NTIxNQ==&mid=2650112990&idx=1&sn=0569084dbb1271b18cc25dfd8794d9a4&chksm=83ffcbe6d21aa97a57ed28aca7559be9d36b7bf547bf75e21a0fca259af3c86c6596fdc0b79f#rd 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号回复“转载”，获取转载须知。

临床1期蛋白降解靶向嵌合体

2025-12-03

·GlobeNewswire-Health Care

Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology

Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCCThe combination continued to show clinically meaningful survival improvement versus sorafenib, a standard first-line treatment for uHCCElevar plans to resubmit its new drug application for camrelizumab/rivoceranib combination therapy in January 2026 FORT LEE, N.J., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the final analysis of its Phase 3 CARES-310 study was published in The Lancet Oncology. The study assessed the efficacy and safety of the combination of Elevar’s drug candidate rivoceranib, an oral TKI, and camrelizumab, a PD-1 inhibitor, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). In the randomized, open-label, international trial (NCT03764293), which included 543 patients at 95 study sites across 13 countries/regions, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement versus sorafenib (median overall survival of 23.8 vs. 15.2 months), a standard first-line treatment for uHCC, and a manageable safety profile. Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026. "Having our Phase 3 study final analysis published in a prestigious journal such as The Lancet Oncology is momentous for Elevar Therapeutics and, even more so, for the global liver cancer patient community,” said Bryan Kim, chief executive officer of Elevar. “The data clearly showed the potential of our combination treatment of camrelizumab and rivoceranib, as it significantly improved survival compared to the standard treatment option. This is evidence that our hard work developing better therapies for patients with few options is paying off. We're proud of everyone on our team and our partners for hitting this milestone, and we’re focused on getting this promising treatment to patients everywhere as soon as possible." Findings:Between June 28, 2019, and March 24, 2021, 543 patients (457 [84%] males; 450 [83%] were Asian) were randomly assigned to receive camrelizumab-rivoceranib (n=272) or sorafenib (n=271). At final analysis on June 14, 2023, the median follow-up was 22.1 months (IQR 11.9-30.3) in the camrelizumab-rivoceranib group and 14.9 months (7.2-28.3) in the sorafenib group. Median overall survival was 23.8 months (95% CI 20.6-27.2) with camrelizumab-rivoceranib and 15.2 months (13.2-18.5) with sorafenib (hazard ratio [HR] 0.64 [95% CI 0.52-0.79]; one-sided p<0.0001). Median progression-free survival was 5.6 months (95% CI 5.5-7.4) with camrelizumab-rivoceranib and 3.7 months (95% CI 3.1-3.7) with sorafenib (HR 0.54 [95% CI 0.44-0.67]; one-sided p<0.0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (104 [39%] of 272 patients in the camrelizumab-rivoceranib group vs. 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysesthesia syndrome (33 [12%] vs. 42 [16%]), increased aspartate aminotransferase (47 [17%] vs. 14 [5%]), and increased alanine aminotransferase (38 [14%] vs. 8 [3%]). Treatment-related serious adverse events were reported in 69 (25%) patients in the camrelizumab-rivoceranib group and 18 (7%) patients in the sorafenib group. Treatment-related deaths occurred in one patient each in the camrelizumab-rivoceranib group (multiple organ dysfunction syndrome) and sorafenib group (respiratory failure and circulatory collapse). About Hepatocellular CarcinomaHepatocellular Carcinoma (HCC) is the most common type of liver cancer and most frequently develops in people with chronic underlying liver inflammation, which may be from viral and non-viral causes. HCC typically has a poor prognosis with limited treatment options and continues to be a diagnosis with an ongoing urgent medical need. More than 800,000 people worldwide are diagnosed with liver cancer each year and it is also a leading cause of cancer deaths, accounting for more than 700,000 annually, according to the American Cancer Society. About RivoceranibRivoceranib, a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR), a primary pathway for tumor angiogenesis. VEGFR inhibition is a clinically validated target to limit tumor growth and disease progression. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications. Ongoing clinical studies include uHCC (in combination with camrelizumab), gastric cancer (as a monotherapy and in combination with paclitaxel), adenoid cystic carcinoma (as a monotherapy) and colorectal cancer (in combination with Lonsurf®). Rivoceranib was the first TKI approved in gastric cancer in China (November 2014). It is also approved in China in combination with camrelizumab as a first-line treatment for uHCC (January 2023). The drug has been studied in more than 6,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs and VEGF inhibitors. Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), in adenoid cystic carcinoma (U.S.) and in uHCC (U.S. and EU). Elevar Therapeutics, Inc. holds the global rights (excluding China) to rivoceranib and has partnered for its development and marketing with HLB-LS in South Korea. Rivoceranib, under the name apatinib, is also approved in China for advanced gastric cancer and in second-line advanced HCC by the Chinese-territory license-holder, Jiangsu Hengrui Pharmaceuticals Company Ltd., (Hengrui Pharma), under the brand name Aitan®. About CamrelizumabCamrelizumab (SHR-1210) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers. Camrelizumab is developed by Hengrui Pharma and has been studied in more than 5,000 patients. Currently, 50 clinical trials are underway in a broad range of tumors (including liver cancer, lung cancer, gastric cancer and breast cancer, etc.) and treatment settings. Camrelizumab, under the brand name AiRuiKa®, is currently approved for eight indications in China, including monotherapy for the treatment of HCC (second-line), in combination with rivoceranib as a treatment for uHCC (first-line), relapsed/refractory classic Hodgkin’s lymphoma (third-line), esophageal squamous cell carcinoma (second-line) and nasopharyngeal carcinoma (third-line or further) and in combination with chemotherapy for the treatment of non-small cell lung cancer (non-squamous and squamous), esophageal squamous cell carcinoma and nasopharyngeal carcinoma in the first-line setting. The U.S. Food and Drug Administration granted Orphan Drug Designation to camrelizumab for advanced HCC in April 2021 and by the EMA in August 2024. In October 2023, Elevar licensed camrelizumab, an anti-PD-1 antibody, for commercialization from Hengrui Pharma worldwide excluding Greater China and Korea. Media Contact: Rosemary Ostmann RoseComm rostmann@rosecomm.com (201) 615-7751

临床结果临床3期孤儿药上市批准免疫疗法

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
转移性胰腺癌	秘鲁	浙江海昶生物医药股份有限公司	2025-05-14
胰腺癌	中国	Bristol Myers Squibb Co.	2024-01-05
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
不能切除性胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2014-12-18
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2013-02-21
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
非小细胞肺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
进展期胃腺癌	临床3期	中国	石药集团欧意药业有限公司	2020-03-01
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04705519 (Pubmed \| EClinicalMedicine)	临床2期	神经内分泌癌二线	79	Nab-paclitaxel plus bevacizumab	繭簾蓋觸夢鹽遞構獵衊(醖鏇艱蓋積顧構夢鹽衊) = 築鹽廠夢鏇壓壓鹹鑰構築繭製廠壓構襯積顧窪 (鏇齋鏇窪鏇壓鑰構醖積, 8.6 ~ 17.4) 更多	积极	2025-12-01
NCT02945800 (CTgov)	临床2期	横纹肌肉瘤 \| 尤文肉瘤 \| 软组织肉瘤 ... 更多	59	nab-Paclitaxel+Gemcitabine	窪膚築鹽膚選簾窪鏇鬱 = 遞鬱衊窪淵餘壓膚觸鏇鬱鑰齋壓壓壓膚膚獵艱 (鹽艱壓糧膚鏇夢襯窪衊, 衊鹽艱蓋鏇膚積餘壓鏇 ~ 齋壓憲糧構壓簾繭廠鹹) 更多	-	2025-12-01
NCT02593175 (CTgov)	临床2期	三阴性乳腺癌 \| 3型乳腺癌	43	Carboplatin+Paclitaxel+Panitumumab	鑰構鏇壓淵鹽願衊築繭 = 顧憲廠遞遞構簾顧鏇醖觸鬱範鏇淵淵鹹窪壓製 (鏇鹽鏇獵襯鹽構餘餘鏇, 襯襯鑰觸簾網淵醖艱膚 ~ 積壓糧衊壓齋醖獵鏇餘) 更多	-	2025-11-06
ChiCTR2000035072 (ESMO2025) 人工标引	临床2期	铂耐药上皮性卵巢癌	17	Sintilimab + PaclitaxeAnlotinibinib	齋廠鏇艱製繭鑰選窪夢(築鏇製範繭餘壓衊鏇餘) = 廠憲選積選鹹齋襯廠獵窪繭淵鹽壓窪遞範襯範 (製願襯鹹窪遞願選製廠, 3.5 ~ NR) 更多	积极	2025-10-17
NCT04769076 (ESMO2025)	临床2期	晚期鼻咽癌	21	NAB-paclitaxel + Cisplatin + PD1 inhibitor + Concurrent chemoradiotherapy	鬱壓選膚淵衊齋鬱構選(鏇願簾築獵鹹鏇構鹹窪) = 憲鑰觸壓廠鏇鏇襯構鹹製憲製鹹鬱醖選鑰鑰憲 (餘憲製鏇遞齋簾獵襯夢 ) 更多	积极	2025-10-17
ESMO2025	N/A	转移性乳腺癌 HR positive \| HER2 negative	30	Paclitaxel + Bevacizumab	艱鏇獵構憲廠獵糧網醖(窪醖壓艱壓窪鏇積繭鑰) = 膚鏇窪範醖鏇鏇鏇蓋襯夢襯網醖積範艱淵鬱顧 (鑰醖餘選網蓋壓簾鹽衊 ) 更多	积极	2025-10-17
NCT04781088 (ESMO2025)	临床2期	复发性子宫内膜癌 \| 铂耐药性卵巢癌 ctDNA	29	Lenvatinib+paclitaxel+pembrolizumab	製繭願齋範顧鹹淵鬱鑰(夢夢範積齋範繭獵糧選) = 觸選蓋窪積鏇鏇壓顧積衊築衊觸獵襯鹹觸繭選 (網襯窪獵憲鑰簾膚選廠 ) 更多	积极	2025-10-17
NCT04781088 (ESMO2025)	临床2期	复发性子宫内膜癌 \| 铂耐药性卵巢癌 ctDNA	29	Lenvatinib+paclitaxel+pembrolizumab (ctDNA clearance or persistently negative)	製繭願齋範顧鹹淵鬱鑰(夢夢範積齋範繭獵糧選) = 憲廠壓鬱願襯築鏇艱襯衊築衊觸獵襯鹹觸繭選 (網襯窪獵憲鑰簾膚選廠 ) 更多	积极	2025-10-17
GeNeS1S (ESMO2025)	临床2期	胰腺癌	30	gemcitabine+nab-paclitaxel+S-1	願醖糧夢遞築襯衊顧選(壓鬱醖願蓋鹹獵製製鑰) = 壓選製鹹衊網齋襯廠鬱獵衊簾艱遞醖蓋齋範選 (淵壓醖襯膚鑰構鏇淵膚 ) 更多	积极	2025-10-17
GeNeS1S (ESMO2025)	临床2期	胰腺癌	30	gemcitabine+nab-paclitaxel+S-1 (primary tumor)	願醖糧夢遞築襯衊顧選(壓鬱醖願蓋鹹獵製製鑰) = 鑰艱餘鬱餘遞鬱齋糧壓獵衊簾艱遞醖蓋齋範選 (淵壓醖襯膚鑰構鏇淵膚 )	积极	2025-10-17
ESMO2025	N/A	-	1,663	paclitaxel+carboplatin (Primary debulking surgery (PDS))	鹹選襯鑰選顧艱鏇醖繭(構襯觸艱製積遞艱積遞): HR = 0.79 (95.0% CI, 0.64 ~ 0.97) 更多	积极	2025-10-17
ESMO2025	N/A	-	1,663	paclitaxel+carboplatin±bevacizumab (Neoadjuvant chemotherapy (NACT) + interval surgery (IDS))		积极	2025-10-17
ESMO2025	N/A	EGFR突变的非小细胞肺癌 PD-L1 expression	408	Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP)	願艱繭網網選鑰廠積襯(製顧憲膚選簾鹽簾獵簾) = 蓋鏇窪觸遞醖鹹醖繭憲鑰網蓋積夢鹹網醖構網 (夢鑰夢蓋蓋積鬱築衊蓋 ) 更多	积极	2025-10-17
ESMO2025	N/A	EGFR突变的非小细胞肺癌 PD-L1 expression	408	Chemotherapy (± bevacizumab)	願艱繭網網選鑰廠積襯(製顧憲膚選簾鹽簾獵簾) = 襯獵鹽衊壓淵餘醖齋構鑰網蓋積夢鹹網醖構網 (夢鑰夢蓋蓋積鬱築衊蓋 ) 更多	积极	2025-10-17